Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new ...
MDCE continues to build upon significant improvements in its financial performance. For fiscal 2025, the Company reported ...
As momentum in lupus research continues to accelerate, the Lupus Research Alliance (LRA), the world's largest private funder ...
VIA Disc ® NP is a sterilized nucleus pulposus allograft derived from human donor nucleus pulposus disc tissue, delivered ...
Analysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.
Lead FDA-track program targets a serious pediatric disease with no FDA-approved treatment and could qualify for a ...
Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel ...
Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Neera Clase as Chief Commercial Officer (CCO), ...
The FDA has outlined a process for allowing a single application to cover multiple variants of a gene therapy. At the same ...
The largest pharmas have a collective $188 billion in firepower to spend on M&A transactions, with all but one signaling a ...
Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to ...
With pressure on GSK’s vaccine business, analysts predict the U.K. pharma will face challenges as it prepares for the loss of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results